Zambon Company S.p.A.

With interest in new drugs for schizophrenia on the rise, and backed by impressive mid-stage data, Newron Pharmaceuticals SpA is increasingly confident that it will soon ink a lucrative partnership

For Newron Pharmaceuticals SpA , 2024 is looking like a transformational year as the Italian biotech moves closer to presenting data from a potentially pivotal study evaluating evenamide in patients

The US FDA’s most recent set of breakthrough therapy designations went to products that are already in advanced development – including one product that had already sought approval and received a comp

Italy’s Newron Pharmaceuticals SpA has initiated an explanatory clinical study of its potential add-on schizophrenia therapy, evenamide, to address potential safety issues raised by regulators in 20